Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer

BACKGROUND: Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Minjiang, Xu, Yan, Zhao, Jing, Li, Ji, Liu, Xiangning, Zhong, Wei, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410567/
https://www.ncbi.nlm.nih.gov/pubmed/34291566
http://dx.doi.org/10.1111/1759-7714.14075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410567/
https://www.ncbi.nlm.nih.gov/pubmed/34291566
http://dx.doi.org/10.1111/1759-7714.14075

Ejemplares similares